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Abstract In order to characterize neuropeptide Y (NPY)
receptors present in human adipocytes, we used selective ligands
together with specific molecular probes able to recognize the
different NPY receptor subtypes. RT-PCR experiments revealed
the presence of Y1 receptor transcripts with Y4 and Y5 and
absence of Y2 signals. Binding studies, using selective radio-
iodinated ligands, detected a high number (Bmax = 497 þ 124
fmol/mg protein) of a high affinity binding site only with
[125I]peptide YY (PYY) and [125I](Leu31,Pro34)PYY. These sites
exhibited a typical Y1 profile as indicated by the rank order of
affinity of NPY analogs and the high affinity of two selective
NPY receptor antagonists, SR120819A and BIBP3226. In
[35S]GTPQS binding experiments, PYY activation was totally
inhibited by SR120819A and BIBP3226. Both compounds
antagonized, with similar efficiency, the antilipolytic effect
exerted by NPY in isolated adipocytes. Finally, PYY and Y1
ligands enhanced adipocyte leptin secretion, an effect totally
prevented by SR120819A. Thus, highly expressed in human
adipocytes, the Y1 receptor sustains the strong antilipolytic effect
of NPY and exerts a positive action on leptin secretion. ß 2000
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Neuropeptide Y (NPY) is a 36 amino acid peptide which
belongs to a family of neuropeptides including NPY, peptide
YY (PYY) and pancreatic polypeptide (PP). NPY is widely
distributed throughout the central and peripheral nervous sys-
tems in mammals where it is co-stored with norepinephrine in
the sympathetic nerve terminals [1]. Related to its widespread
distribution, NPY exerts a variety of biological e¡ects espe-
cially on cardiovascular regulation, food intake, metabolism,
behavioral and endocrine functions via several receptor sub-
types. Five distinct NPY receptors have been cloned belong-
ing to the seven transmembrane G protein-coupled receptor
family: Y1, Y2, Y4, Y5, Y6 and a putative Y3 receptor which
remains to be elucidated [2]. Among various actions, NPY
and PYY exert a strong, direct antilipolytic e¡ect on adipo-
cytes through receptors previously named PYY-preferring re-
ceptors [3,4]. These receptors also seem to be expressed in
other cell types such as rat small intestine [5] and kidney
proximal tubule cells [6] and are distinguished by a higher
binding a⁄nity for PYY than for NPY. PYY-preferring re-
ceptors are negatively coupled to adenylyl cyclase and their
inhibitory e¡ect is sensitive to the pertussis toxin. This type of
receptor appears to be a 62 kDa protein in adipocytes and a
44 kDa glycoprotein in the intestine. To date, PYY-preferring
receptors have not been successfully cloned or clearly identi-
¢ed [3,4,7].
In an attempt to precisely characterize the NPY/PYY re-
ceptors present in mature human adipocytes, we used new
selective peptide and non-peptide NPY ligands together with
speci¢c molecular probes able to recognize the di¡erent NPY
receptor subtypes. Functional characterization of the NPY
receptor involved in the antilipolytic e¡ect of NPY was per-
formed by studying [35S]GTPQS binding activation and by
measuring fat cell lipolysis in the presence of selective NPY
Y1 receptor antagonists. We clearly demonstrated that a typ-
ical Y1 receptor is highly expressed in human adipocytes and
supports the antilipolytic e¡ect of NPY and PYY. We also
showed that these peptides are able to regulate leptin produc-
tion via NPY Y1 receptor activation.
2. Materials and methods
2.1. Materials
2.1.1. Chemicals. The two selective NPY Y1 receptor antagonists
SR120819A [8] and BIBP3226 [9] were synthesized in Sano¢-Synthe-
labo (Toulouse, France). They were dissolved in DMSO at 1032 M
and then diluted in the appropriate test solvent. NPY, PYY and frag-
ments were from Neosystems (Strasbourg, France). Bovine serum
albumin was from Biosepra (Paris, France). Collagenase and enzyme
for glycerol assays came from Boehringer Mannheim (Mannheim,
Germany). EDTA and HEPES were purchased from Merck-Clevenot
(Nogent sur Marne, France). The radioligands, [125I]PYY (human),
[125I](Leu31,Pro34)PYY (human), [125I](3^36)-PYY (human), [125I]PP
(human) and [125I]PP (rat) (2000 Ci/mmol) and [35S]GTPQS (1250
Ci/mmol) were from New England Nuclear, Life Sciences (Les Ulis,
France). Radioimmunoassay (RIA) kits for leptin were from RpD
Systems Europe Ltd. (Abingdon, UK).
2.1.2. Biological materials. Adipose tissue was obtained from
healthy female donors (30^55 years old) undergoing abdominal plastic
surgery for cosmetic reasons. Tissue collection was performed accord-
ing to our national ethical rules. Six to 12 independent preparations
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were studied after adipocyte isolation by collagenase digestion.
Ready-to-use cultured human di¡erentiated adipocytes grown in 96
well format were shipped from Stratagene Inc. (La Jolla, CA, USA).
2.2. NPY receptor expression in human adipocytes
Quanti¢cation of mRNA encoding human L2-microglobulin and
human NPY gene receptors (NPY-r) was performed with the human
adipocyte cDNA purchased from Clontech Laboratories, Inc. (Palo
Alto, CA, USA). DNA ampli¢cations were carried out in PCR bu¡er
(PE Biosystem, Courtaboeuf, France) containing 6 Wl of cDNA solu-
tion from dog cDNA preparation or 1 ng of cDNA from Clontech,
0.1 mM dNTP (Amersham Pharmacia Biotech, Orsay, France), 0.25
WM of each 5P and 3P primers and 0.5 U Taq polymerase (PE Bio-
system,) in a ¢nal volume of 20 Wl. The mixture was ampli¢ed with the
GeneAmp PCR 9600 Thermal cycler (PE Biosystem, Courtaboeuf,
France). The thermal reaction pro¢le consisted of a denaturation
step at 95‡C for 20 s, annealing at 60‡C for 30 s and an extension
step at 75‡C for 20 s. The reaction was performed for 40 cycles. After
PCR, 5 Wl loading bu¡er (Novex, San Diego, CA, USA) was mixed
with 10 Wl PCR products and electrophoresed on a 3% agarose gel in
the presence of ethidium bromide with 123 bp DNA markers (Gibco
BRL Life Technologies, Cergy Pontoise, France) as molecular weight
controls. Gene-speci¢c sense and antisense oligonucleotide primers
used for PCR and internal oligonucleotide probes used for Southern
blot hybridization were designed from published human NPY-r se-
quence data. The oligonucleotides used were purchased from Genset
(Paris, France). All the primers were 20 residue oligonucleotides with
50% G+C content and lacking 3P complementary between primer
pairs. L2-Microglobulin primers (as internal control) (1): sense
5P-GCTTACATGTCTCG-3P ; antisense 5P-GATGCTGCTTACATG-
TCTCG-3P. NPY1-r primers: sense 5P-925/CATGATGGACAAGAT-
GAGAG-3P ; antisense 5P-1257/GTGGACATGGCTATTGTTTC-3P.
NPY2 primers: sense 5P-599/GATCATCCCGGACTTTGAGA-3P,
antisense 5P-781/GCTCCAGGACTGACATGGTT-3P. NPY4-r prim-
ers: sense 5P-441/GAGGCATCAGCTCATCATCA-3P, antisense 5P-
627/GACCACCTTATCTGCCAGGA-3P. NPY5-r primers: sense 5P-
564/TCTGTTCTCCCCTTCCAGTG-3P, antisense 5P-861/ACCTGA-
GGCCCACTCTTTTT-3P.
The expected size of the amplicons was 268 bp for L2-microglobu-
lin, 383 bp for NPY1-r, 183 bp for NPY2-r, 187 bp for NPY4-r
and 298 bp for NPY5-r. The speci¢city of each primer pair was
analyzed by running PCR with human whole brain cDNA (Clontech),
and Southern analysis of the PCR products with the correspond-
ing internal oligonucleotide probe (data not shown) as already de-
scribed [10]. Total adipocyte RNA was extracted using the Qiagen
RNeasy kit (Qiagen, Hilden, Germany) and stored at 380‡C until
used.
2.3. Isolation of human adipocytes and membrane preparation
Adipocytes were isolated using the Rodbell method [11] in Krebs^
Ringer bicarbonate bu¡er (pH 7.4) containing 0.5 mg/ml collagenase,
3.5% bovine serum albumin and 6 mM glucose as previously de-
scribed [12]. Isolated adipocytes were used immediately either for lip-
olysis measurements or membrane preparations for binding studies.
The preparation of adipocyte membranes was performed according to
Castan et al. [4]. At the end of the washing procedure, crude adipo-
cyte membranes were suspended in the lysing bu¡er at a ¢nal concen-
tration of 0.5^2 mg/ml and stored as aliquots in liquid nitrogen until
used. Protein concentration was determined by the method of Brad-
ford using bovine serum albumin as a standard [13].
2.4. Binding assays with various NPY radioiodinated ligands
Adipocyte membranes (0.005^0.02 mg/ml) were incubated for 60
min at 30‡C in a Krebs^Ringer bu¡er (pH 7.4) containing 20 mM
HEPES, 1% bovine serum albumin, 0.33 mg/ml bacitracin and 0.1 nM
of radioligand ([125I]hPYY, (Leu31,Pro34)-hPYY, (3^36)-hPYY, hPP
or rPP) as previously described [8]. Non-speci¢c binding was deter-
mined in the presence of 0.3 WM porcine NPY when using [125I]PYY
ligands or 0.3 WM human PP when rat and human [125I]PP were used.
Competition experiments were carried out in the presence of 0.1 nM
[125I]hPYY and various concentrations of the compound to be tested.
For saturation experiments increasing concentrations (0.01^2 nM) of
[125I]hPYY and [125I](Leu31,Pro34)-hPYY were used. All experiments
were carried out in duplicate. Data from binding experiments (i.e.
apparent equilibrium dissociation constant (Kd), maximum binding
capacity (Bmax), IC50 (concentration of inhibitor required to obtain
50% inhibition of the speci¢c binding) and Hill coe⁄cient (nH)) were
analyzed using a non-linear regression program [14].
2.5. [35S]GTPQS binding
Crude adipocyte membranes (0.030 mg/ml) were incubated in bind-
ing bu¡er with [35S]GTPQS in the presence of the appropriate concen-
tration of agonist, hPYY (100 nM), and GDP 1036 M for 45 min at
25‡C. Non-speci¢c binding was determined in the presence of 1035 M
unlabelled GTPQS. The reaction was stopped by ¢ltration through
Whatman GF/B ¢ber ¢lters. The radioactivity bound to ¢lters was
measured by scintillation counting. All results are expressed as per-
centage of the basal activity. Values are the mean þ S.E.M. of three to
four experiments.
2.6. Lipolysis measurements
The lipolytic activity was analyzed on isolated adipocytes obtained
after collagenase digestion. A fat cell suspension (1000^2000 cells) in a
Krebs^Ringer bicarbonate bu¡er, pH 7.4, was incubated in plastic
vials with gentle shaking at 37‡C. After 90 min, the incubation tubes
were placed in an ice bath, the adipocytes were separated from the
bu¡er, and 20^50 Wl of the infranatant removed for the radioenzy-
matic determination of glycerol according to the method of Bradley
and Kaslow [15]. The glycerol produced by the cells was taken as an
index of lipolysis. Pharmacological agents were added just before the
beginning of the incubation in 10 Wl portions in vehicle to obtain a
suitable ¢nal concentration. Adenosine deaminase (ADA) was in-
cluded in the incubation medium to prevent inhibition due to adeno-
sine released by the fat cells ; as previously reported, this procedure
allows a more accurate de¢nition of the antilipolytic e¡ects. The lip-
olytic activity of all isolated fat cell batches was checked using 1 WM
isoproterenol. All experiments were performed in duplicate. Values
are given as means þ S.E.M. (n = 6). Student’s paired t-test was used
for statistical evaluation.
2.7. Leptin assays
By using cultured ready-to-use human di¡erentiated adipocytes
grown in 96 well plates, we measured the in£uence of various NPY
analogs on leptin production. These mature adipocytes were obtained
from subcutaneous preadipocytes cultured in a di¡erentiation medium
as previously described [16]. The batch of cells used was at the third
passage and had been validated by the supplier using the adipocyte-
speci¢c genes: aP2 (fatty acid binding protein), peroxisome prolifer-
ator-activated receptor Q and leptin. They exhibited the typical mor-
phology of mature adipocytes with multiple lipid vesicles (Fig. 5A).
Culture medium was changed every 2 days. Cells were treated with or
without 1037 M NPY analogs (hPYY, (Leu31,Pro34)-hNPY and rPP)
in the presence or absence of SR120819A (1036 M). 100 Wl aliquots of
adipocyte culture medium were taken at various times for leptin mea-
surements by RIA (22, 50 and 69 h after the beginning of the treat-
ment) and replaced by 100 Wl of medium containing the appropriate
treatments. All compounds were dissolved in culture medium. Data
are means þ S.E.M. (n = 4^6). Statistical analysis of data was per-
formed by means of multifactorial analysis of variance (ANOVA),
with repeated measurements. Post hoc comparisons to the respective
control were performed with Dunnett’s test. Statistical signi¢cance
was set at P6 0.05.
3. Results
3.1. Expression of NPY receptor genes in human adipocytes
Using speci¢c primers, quanti¢cation of human NPY gene
receptors was performed from PCR analysis of mRNA ex-
tracted from either isolated human adipocytes or commercial
human adipocyte cDNA. The presence of human L2-micro-
globulin transcripts was also assessed as a control. As shown
in Fig. 1, single bands of 383 bp (NPY Y1), 187 bp (NPY Y4),
298 bp (NPY Y5) and 268 bp (L2-microglobulin) were specif-
ically generated with speci¢c primers. No NPY Y2-r transcript
was detected. These PCR products have the sizes predicted
from the genomic sequences. Similar bands were obtained
using mRNA from either freshly isolated or cultured human
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adipocytes as well as from commercially available human adi-
pocyte cDNA (not shown).
3.2. Biochemical characterization of human adipocyte NPY
receptors
Preliminary binding studies, performed on human adipo-
cyte membranes in the presence of various receptor subtype-
selective radioiodinated NPY ligands, evidenced high amounts
of speci¢c labelling when using the natural hormone,
[125I]hPYY, and (Leu31,Pro34)-hPYY, known as a Y1, Y4
and Y5 ligand. Very low or no speci¢c binding (even at a
high adipocyte membrane concentration) was detected using
either [125I]hPYY(3^36), a Y2 and Y5 probe, [125I]hPP, a Y4
and Y5 ligand, or [125I]rPP, a speci¢c Y4 receptor radioligand
(not shown). These data are consistent with a majority of
NPY Y1 receptors in our preparation. Saturation binding ex-
periments performed on human adipocyte membranes with
[125I]hPYY and [125I](Leu31,Pro34)-hPYY indicated that the
speci¢c binding observed was saturable. As shown in Fig. 2,
Scatchard analysis of these data gave linear plots consistent
with the presence of a single class of high a⁄nity binding sites
having apparent Kds of 0.81 þ 0.11 and 1.26 þ 0.14 nM for
[125I]hPYY and [125I](Leu31,Pro34)-hPYY, respectively. It is
important to note that both ligands identi¢ed a similar bind-
ing capacity when used simultaneously on the same adipocyte
preparation (for example, see Fig. 2). [125I]hPYY binding
demonstrated very high binding capacity with a mean Bmax
value of 497 þ 127 fmol/mg protein (i.e. approximately 50 000
sites/adipocyte). Signi¢cant variations were observed with in-
dividual tissue donors (from 174 to 780 fmol/mg protein
which corresponds to 15 000^75 000 sites/fat cell).
In competition binding experiments, the relative a⁄nities of
several reference peptide and non-peptide NPY compounds
were also studied to further characterize [125I]PYY receptors
expressed in human adipocytes. As shown in Table 1, the
labelled receptor exhibited a typical Y1 pro¢le, as de¢ned in
a recent classi¢cation [2]: Y4 (rat and human PP), Y5
(D32Tryp-NPY, (3^36)-hPYY and hPP) and Y2 ((13^36)-
Fig. 1. NPY receptor gene expression in human adipocytes. NPY-r
expressions were obtained after PCR ampli¢cation of cDNA from
human di¡erentiated adipocytes using speci¢c primers. Negative
control was performed with no cDNA. Internal control was ob-
tained by PCR of L2-microglobulin gene. The size of the ampli¢ed
products is indicated in bp on the right. PCR products were sepa-
rated by electrophoresis on 3% agarose gel in the presence of ethidi-
um bromide with 123 bp DNA markers as molecular weight con-
trols.
Fig. 2. Saturation of (F) [125I]hPYY- and (b) [125I](Leu31,Pro34)-
hPYY-speci¢c binding to human isolated adipocyte membranes. In-
cubations were carried out as described in Section 2 in the presence
of increasing concentrations of 125I ligands with membranes (12 Wg
protein) for 1 h at 30‡C. Each point is the mean calculated from a
typical experiment performed in duplicate and repeated three times
without noticeable changes.
Table 1
Inhibition of [125I]PYY binding to human adipocyte membranes by
reference peptide and non-peptide NPY ligands
IC50 (nM)
Peptides
hPYY 0.89 þ 0.09
hNPY 1.09 þ 0.22
(Leu31,Pro34-hNPY 1.75 þ 0.65
(3^36)-hPYY 121 þ 47
(13^36)-pNPY 373 þ 214
rPP s 1000
hPP 105 þ 12
D32Tryp-hNPY s 1000




BIBP3226 10 þ 6
SR120819A 27 þ 7
Half maximum speci¢c binding (IC50) was calculated according to
[14]. Values are means þ S.D. of three to six independent determina-
tions performed in duplicate.
Fig. 3. Inhibition of [125I]PYY-speci¢c binding to membranes of iso-
lated human adipocytes by reference peptide and non-peptide NPY
ligands. Incubations were carried out in the presence of 0.1 nM
[125I]hPYY and increasing concentrations of the compound to be
tested: hPYY (a), hNPY (E), (Leu31,Pro34)-hPYY (S), BIBP3226
(b), SR120819A (P) and (3^36)-hPYY (F). Data are the mean of
duplicate determinations (n = 3^6).
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pNPY and (3^36)-hPYY) ligands had low a⁄nities whereas
(Leu31,Pro34)-hPYY, a Y1 probe, and the selective non-pep-
tide Y1 receptor antagonists BIBP3226 and SR120819A dis-
played high binding a⁄nities. As shown in Fig. 3, these latter
molecules displaced [125I]hPYY dose-dependently. In every
case the proportion of BIBP3226- or SR21819A-insensitive
binding sites accounted for less than 5% of the speci¢c binding
demonstrating that the great majority of sites labelled by
[125I]hPYY are Y1 receptors. Dose^response curves for all
compounds tested gave a linear Hill plot and pseudo Hill
coe⁄cient (nH) near unity (not shown).
3.3. Functional studies in isolated human adipocytes
3.3.1. [35S]GTPQS binding. NPY receptors are coupled to
heterotrimeric, pertussis toxin-sensitive G proteins and ago-
nist activation leads to the inhibition of adenylyl cyclase. We
used [35S]GTPQS binding as a functional measure of NPY
receptor activation in human adipocytes. Human PYY stimu-
lated [35S]GTPQS binding to adipocyte membranes with an
EC50 value of 16 þ 7 nM. Additionally (Leu31,Pro34)-hNPY
but neither (3^36)-hPYY nor human and rat PP increased
[35S]GTPQS binding. BIBP3226 and SR120819A, known as
selective Y1 receptor blockers, dose-dependently antagonized
hPYY (100 nM)-stimulated [35S]GTPQS binding with Ki val-
ues of 6 þ 3 and 27 þ 3 nM (n = 3), respectively. These results
are consistent with the binding data (Table 1).
3.3.2. Lipolysis measurements. On human isolated adipo-
cytes, NPY and PYY promoted a dose-dependent inhibition
of lipolysis prestimulated by ADA [12]. As shown in Fig. 4A,
hNPY (100 nM) signi¢cantly antagonized the lipolytic activity
observed in the presence of ADA (4 Wg/ml) by about 40%,
consistent with previous results. In this model, the glycerol
production was taken as an index of the lipolytic rate and
the validity of each preparation was controlled on the basis
of its isoproterenol response. Tested under similar experimen-
tal conditions, SR120819A and BIBP3226 (1039^1036 M)
dose-dependently antagonized NPY inhibition with a similar
potency (Fig. 4B). The highly selective pro¢le of these mole-
cules further supports the involvement of NPY Y1 receptors
in the antilipolytic e¡ect of NPY on human adipocytes.
3.3.3. Leptin production in di¡erentiated human
adipocytes. The cultured human adipocytes used demon-
strated di¡erentiated adipocyte-speci¢c physiology as evi-
denced, in particular, by their capacity for leptin produc-
tion and as shown by their typical morphology with
multiple intracellular lipid vesicles, in agreement with the ma-
ture adipocyte phenotype (Fig. 5A). Moreover, we detected
signi¢cant amounts of speci¢c binding with [125I]hPYY
and [125I](Leu31,Pro34)-hPYY but no speci¢c labeling with
[125I]hPYY(3^36) or [125I]hPP as previously seen with isolated
adipocyte membranes (not shown). Cell pretreatment of these
cells with 100 nM hPYY and (Leu31,Pro34)-hNPY enhanced
leptin release at the di¡erent times studied as compared with
the vehicle-treated control (Fig. 5B). This e¡ect was prevented
by pretreating these cells with the selective Y1 receptor antag-
onist SR120819A (1 WM). The Y4, Y5 ligand, hPP, had no
e¡ect on leptin production (not shown). All these data are in
agreement with a speci¢c e¡ect of NPY/PYY on peripheral
leptin secretion via a Y1 receptor-mediated pathway.
4. Discussion
The present study characterized the nature and the role of
the NPY receptors expressed in human di¡erentiated adipo-
cytes. Using selective molecular probes directed against the
di¡erent human NPY receptors and speci¢c ligands in binding
and functional studies, we clearly demonstrated that the Y1
receptor is expressed in high amounts by human adipocytes
and is responsible for the antilipolytic e¡ect of NPY/PYY on
fat cells. Stimulation of the Y1 receptor is also able to control
leptin production in these cells.
In a ¢rst set of experiments, the molecular expression of the
di¡erent NPY receptor transcripts in human adipocytes was
studied by PCR analysis using selective primers for NPY Y1,
Y2, Y4 and Y5 receptors. NPY Y1 transcripts together with
signi¢cant amounts of NPY Y4 and NPY Y5 receptor
mRNAs were detected, whereas no Y2 signal was found in
this tissue.
Binding experiments performed on isolated human adipo-
cyte membranes clearly identi¢ed sites exhibiting a classical
Y1 pro¢le as referred to in the recently published NPY clas-
si¢cation [2]. Firstly, the identi¢cation performed with sub-
type-selective radioiodinated NPY ligands showed the absence
of speci¢c binding with [125I]hPYY(3^36) (a Y2 and Y5
probe), [125I]hPP (a Y4 and Y5 ligand) and [125I]rPP (a speci¢c
Y4 probe), whereas only the natural hormone [125I]hPYY and
(Leu31,Pro34)-hPYY (Y1, Y4, Y5) identi¢ed a single class of
high a⁄nity binding sites with a similar binding capacity, in
accordance with a unique Y1 receptor population in our prep-
aration. Secondly, competition binding studies performed
with selective peptide and non-peptide ligands showed a
high a⁄nity for PYY and con¢rmed the Y1 nature of the
site identi¢ed based upon the following rank order of a⁄n-
ity: hPYYv hNPYW(Leu31,Pro34)-hNPYsBIBP3226WSR-
Fig. 4. E¡ect of the selective NPY Y1 receptor antagonists
BIBP3226 and SR120819A on NPY-induced lipolysis inhibition in
human isolated fat cells. A: E¡ect of hNPY (100 nM) on ADA
(4 Wg/ml)-stimulated lipolysis. Spontaneous basal lipolysis corre-
sponds to 0.243 þ 0.047 Wmol/100 mg lipid/90 min glycerol release.
Results are means þ S.E.M. of six separate experiments performed in
duplicate. hNPY signi¢cantly antagonized the lipolytic activity
measured in the presence of ADA. Comparison (ADA+NPY vs.
ADA) was performed using Student’s paired t-test: *P6 0.05.
B: Dose-dependent antagonism of SR120819A and BIBP3226 on
100 nM hNPY antilipolytic e¡ect measured in the presence of
ADA. Results are means þ S.E.M. of six separate experiments per-
formed in duplicate. Comparison with the control (ADA+NPY)
was performed using Student’s paired t-test: *P6 0.05.
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120819As hPPW(3^36)-hPYYW(13^36)-pNPYs rPPWD-
32Tryp- hNPY. Of note, the two well-known selective Y1 re-
ceptor antagonists, BIBP3226 and SR120819A, completely
displaced radioligand binding with high a⁄nity. Thirdly, there
is a strict correlation between the binding characteristics and
the biological responses observed in human adipocytes: PYY
and the Y1 ligand, (Leu31,Pro34)-hNPY, equally activated
[35S]GTPQS binding, which was totally blocked by the selec-
tive Y1 receptor antagonists SR120819A and BIBP3226.
These two antagonists also blocked the antilipolytic e¡ect
evoked by hPYY in human isolated adipocytes with a similar
potency. In these functional studies, we were unable to ¢nd
any role for potential Y4 and/or Y5 receptors present in these
fat cells. We can hypothesize that even if the Y4 and Y5
mRNAs were detected in human di¡erentiated adipocytes,
the proteins are not or poorly expressed. Discrepancies be-
tween mRNA existence and receptor expression have already
been reported in several systems and could be explained by
the highly sensitive PCR method able to amplify low abun-
dance mRNAs. A low level or absence of transcription togeth-
er with a loss of these sites during the experiments cannot be
excluded. It is also questionable if there is any role of Y4 and
Y5 receptors in early stages of adipocyte maturation and/or
di¡erentiation.
Some years ago, Valet et al. described a powerful antilipo-
lytic e¡ect of NPY/PYY in dog [3] and in human [12] adipo-
Fig. 5. E¡ect of NPY analogs in the presence or absence of SR120819A on leptin secretion in cultured di¡erentiated human adipocytes. A:
Morphology of di¡erentiated human adipocytes seeded in 96 well plates. B: Kinetics of leptin production after adding 100 nM hPYY,
(Leu31,Pro34)-hNPY or culture medium vehicle in the presence (hatched) and in the absence (open) of 1 WM SR120819A (SR). Values are
means þ S.E.M. of four (treated) to six (control) determinations. Di¡erences were considered signi¢cant when P6 0.05.
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cytes mediated by PYY-preferring receptors. Atypical recep-
tors exhibiting a preference for PYY versus NPY have also
been reported in some systems such as the rat intestine [5] and
in a mouse renal proximal tubule cell line where PYY was 2^
10 times more potent than NPY [6]. Due to the limited num-
ber of speci¢c pharmacological tools available at this time and
to the high number of NPY receptor subtypes, a clear char-
acterization of these sites was not possible. Marked species-
speci¢c di¡erences have been observed for NPY receptors in
terms of pharmacological properties and localization [17]. For
example, rodent CNS is rich in Y1 receptors whereas the
human brain is almost devoid of Y1 receptors [18] ; similarly,
prejunctional Y2 receptors are present in the rat vas deferens
whereas a Y1 subtype has been identi¢ed in the rabbit [19].
Here, we report that functional Y1 receptors are present in
human adipocytes, in contrast to previous work showing that
in dog adipocytes a Y2 or Y2-preferring subtype controls lip-
olysis [3]. In rat adipose tissue, dual control of lipolysis by
NPY Y1 and Y2 receptor subtypes has been proposed [7]. In
other species such as rabbit and guinea pig absent or very low
antilipolytic responses to NPY/PYY have been reported [4].
It is also important to note the large number of Y1 sites
found in human adipocytes (Bmax : 497 þ 124 fmol/mg protein,
i.e. 50 000 sites/cell), close to that already reported for K2-
adrenoceptors [3]. This value is more than 10 times higher
than previously reported for putative PYY Y1-preferring re-
ceptors in this tissue but the origin of adipose tissue and the
experimental conditions likely explain these di¡erences. In the
present work we also observed signi¢cant variations in Y1
receptor density according to the donors (15 000^75 000
sites/fat cell). It is questionable if there are any fat cell size-
dependent di¡erences that could explain this variability. In-
terestingly, it has been shown for K2 receptors in di¡erent
species (hamster, rat, dog and human) that adipocyte hyper-
trophy is associated with a speci¢c increase in K2 receptor
number [20].
The potent antilipolytic e¡ect described for the NPY/PYY
system leads one to expect that Y1 receptor antagonists could
be very useful tools for regulating/decreasing lipid accumula-
tion in human fat cells. Surprisingly, mice lacking the Y1
receptor exhibit moderate obesity with increase in body fat
without hyperphagia. These data are inconsistent with a
prominent physiological role of Y1 receptors in fat accumu-
lation. However, the lipolytic role of Y1 receptors in mice is
not known and reduced locomotor activity observed in Y1
knock-out animals might account for the decreased energy
expenditure and subsequent increased fat deposits [21]. These
observations in Y1 knock-out mice are also inconsistent with
results showing inhibition of feeding and weight reduction in
mice treated with Y1 receptor antagonists. Compensatory
mechanisms involving other hormones or receptors are highly
probable in these animals.
Finally, the present work establishes the role of NPY Y1
receptors in the control of leptin production by human adi-
pocytes. This protein is secreted into the blood stream by only
mature white adipocytes. One function of leptin is to commu-
nicate the status of fat stores to the brain although a number
of new functions have recently been revealed. We demonstrate
that PYY and a Y1 ligand enhanced leptin release, an e¡ect
which is totally blocked by a selective Y1 receptor antagonist.
NPY-related modulation of leptin release might represent a
peripheral feedback mechanism in the control of leptin secre-
tion. Thus, an increase in NPY/PYY plasma levels could en-
hance adipocyte leptin secretion. In turn, this hormone, via
speci¢c binding to hypothalamic receptors, inhibits the expres-
sion and synthesis in the hypothalamic arcuate nucleus of
NPY, a strong orexigenic signal. Therefore, an increase in
circulating leptin decreases NPY production and food intake
and increases energy expenditure for protection from high fat
diet-induced obesity and insulin resistance and to limit further
adipocyte hypertrophy.
It has been shown that leptin expression and secretion is
proportional to adipocyte size and under the control of
cAMP. Agents that increase intracellular cAMP, such as L-
adrenergic agonists or dibutyryl cAMP itself, have been
shown to decrease leptin mRNA expression and leptin secre-
tion [22,23]. As expected, NPY Y1 receptor stimulation, which
should reduce cAMP levels, is shown to have the opposite
e¡ects of L-agonists on leptin release.
In conclusion, the functional receptors involved in the anti-
lipolytic e¡ect of NPY/PYY in human adipocytes ful¢ll all the
criteria of the recently cloned Y1 receptor and corresponds to
the PYY-preferring receptor proposed many years ago. In
addition to the well-established central role of NPY as an
hypothalamic neuropeptide controlling food intake, we pro-
pose a peripheral action for this hormone in regulating feed-
ing behavior through modulation of leptin release from white
adipocytes. The physiological relevance of this observation
remains to be established in vivo.
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